Should all patients with psoriasis receive statins? Analysis according to different strategies

Abstract Background: Different strategies have been proposed for the cardiovascular risk management of patients with psoriasis. Objective: To estimate the cardiovascular risk and evaluate two cardiovascular prevention strategies in patients with psoriasis, analyzing which proportion of patients would be candidates to receive statin therapy. Methods: A retrospective cohort was selected from a secondary database. All patients >18 years with psoriasis without cardiovascular disease or lipid-lowering treatment were included. The atherosclerotic cardiovascular disease calculator (2018 American College of Cardiology/American Heart Association guidelines) and the Systematic Coronary Risk Evaluation risk calculator (2016 European Society of Cardiology/European Society of Atherosclerosis guidelines) were calculated. The SCORE risk value was adjusted by a multiplication factor of 1.5. The recommendations for the indication of statins suggested by both guidelines were analyzed. Results: A total of 892 patients (mean age 59.9 ± 16.5 years, 54.5% women) were included. The median atherosclerotic cardiovascular disease calculator and Systematic Coronary Risk Evaluation values were 13.4% (IQR 6.1-27.0%) and 1.9% (IQR 0.4-5.2), respectively. According to the atherosclerotic cardiovascular disease calculator, 20.1%, 11.0%, 32.9%, and 36.4% of the population was classified at low, borderline, moderate, or high risk. Applying the Systematic Coronary Risk Evaluation, 26.5%, 42.9%, 20.8%, and 9.8% of patients were stratified as having low, moderate, high, or very high risk, respectively. The proportion of subjects with statin indication was similar using both strategies: 60.1% and 60.9% for the 2018 American College of Cardiology/American Heart Association and 2016 European Society of Cardiology/European Society of Atherosclerosis guidelines, respectively. Study limitations: This was a secondary database study. Data on the severity of psoriasis and pharmacological treatments were not included in the analysis. Conclusion: This population with psoriasis was mostly classified at moderate-high risk and the statin therapy indication was similar when applying the two strategies evaluated.

Estudio transversal: evaluación de prevalencia de comorbilidades metabólicas y factores de riesgo cardiovascular, y su correlación con la severidad clínica, en 106 pacientes con psoriasis / Prevalence of metabolic comorbidities and cardiovascular risk factors in patients with psoriasis: cross-sectional study

Introducción: Diversos estudios epidemiológicos han demostrado que los pacientes con psoriasis presentan mayor mortalidad general, mortalidad cardiovascular (CV) e incidencia de infarto al miocardio que la población general. Esto se explican o sólo por la mayor prevalencia de factores de riesgo CV clásicos (obesidad, diabetes, hipertensión arterial, entre otros) en estos pacientes, sino que también la psoriasis constituye un factor de riesgo CV independiente en directa relación con su severidad, con mayor impacto en pacientes jóvenes. Objetivos: Evaluar la prevalencia de comorbilidades metabólicas y factores de riesgo CV en 106 pacientes con psoriasis, y su correlación su severidad clínica. Además de comparar dichas prevalencias con las reportadas por la Encuesta Nacional de Salud (ENS) 2010 para la población chilena. Material y método: Se realizó una evaluación antropométrica y una encuesta sobre antecedentes mórbidos y de la psoriasis a 106 pacientes. Se definieron dos grupos de severidad. Se compararon prevalencias entre los grupos de severidad, así como entre la muestra total y la población chilena. Posteriormente se realizó la comparación considerando exclusivamente al grupo etario de 25 a 64 años (84,8 por ciento, tanto para hombres y mujeres. También se compararon prevalencias entre el grupo de pacientes jóvenes con psoriasis severa y la ENS, siendo éste el grupo de mayor riesgo CV asociado a la psoriasis. Resultados: La muestra correspondió a 106 pacientes, 47 mujeres y 59 hombres, con edad media de 43,5 +/- 14 años. La mitad presentó sobrepeso, un 26 por ciento peso normal y un 34 por ciento obesidad, con IMC promedio de 27,8 kg/m2 y gran prevalencia de comorbilidades metabólicas y factores de riesgo CV, siendo los más frecuentes el tabaquismo (41 por ciento) y la hipertensión arterial...

Background: Epidemiologic studies have demonstrated that patients with psoriasis have an increased risk of mortality, cardiovascular (CV) mortality and myocardial infarction, than general population. Some explanation for this is related to an increased incidence of classical CV risk factors (e.g: obesity, diabetes, blood hypertension) on psoriasis patients. Additionally, psoriasis itself is considered as an independent CV risk factor, directly related to its severity and with higher impact on young patients. Objective: To determinate the prevalence of metabolic comorbidities and CV risk factors in patients with psoriasis, and its correlation with the severity of the psoriasis. To compare such prevalence with those reported by the national health database for Chilean population developed in 2010. Materials and Methods: An observational and analytic study was conduced at the Dermatology Department of the Pontificia Universidad Católica de Chile. Patients with psoriasis were evaluated and classified as having as severity in two groups. The prevalence of metabolic comorbidities was determined, comparing outcomes among patients with mild and severe psoriasis and between all psoriasis patients and Chilean population. Results: One hundred and six patients with psoriasis were included in the study. The mean (SD) age was 43.5 (14) years and 55.6 percent were male. Overweight was present on half of the patients, normal weight was present on 26 percent, and obesity was present on 34 percent. Mean body mass index (IMC) was 27.8kg/m2. The most frequent CV risk factor was tabaquism (41 percent), followed by blood hypertension (22.6 percent). The group with severe psoriasis presented higher prevalence of obesity (31.6 vs.13 percent, p=0.02) and abdominal obesity (86.7 vs. 76 percent, p=0.04),that the group with mild psoriasis...